WNK-IN-12

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 562104

CAS#: 2123483-49-6

Description: WNK-IN-12 is a potent, selective and orally active inhibitor of WNK1 kinase.

Chemical Structure

img
WNK-IN-12
CAS# 2123483-49-6
Instruction

Theoretical Analysis

MedKoo Cat#: 562104
Name: WNK-IN-12
CAS#: 2123483-49-6
Chemical Formula: C21H18D3Cl2N5OS
Exact Mass: 464.10
Molecular Weight: 465.410
Elemental Analysis: C, 54.20; H, 5.20; Cl, 15.23; N, 15.05; O, 3.44; S, 6.89

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: WNK-IN-12; WNK IN 12; WNKIN12; WNK inhibitor 12; WNK inhibitor-12;

IUPAC/Chemical Name: (5-Chloro-2-(2-((methyl-d3)amino)thiazol-4-yl)pyridin-4-yl)(4-(4-chlorobenzyl)piperazin-1-yl)methanone

InChi Key: MVXAYIXYYOVALX-FIBGUPNXSA-N

InChi Code: InChI=1S/C21H21Cl2N5OS/c1-24-21-26-19(13-30-21)18-10-16(17(23)11-25-18)20(29)28-8-6-27(7-9-28)12-14-2-4-15(22)5-3-14/h2-5,10-11,13H,6-9,12H2,1H3,(H,24,26)/i1D3

SMILES Code: O=C(C1=CC(C2=CSC(NC([2H])([2H])[2H])=N2)=NC=C1Cl)N3CCN(CC4=CC=C(Cl)C=C4)CC3

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 465.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Vorontsova I, Donaldson PJ, Kong Z, Wickremesinghe C, Lam L, Lim JC. The modulation of the phosphorylation status of NKCC1 in organ cultured bovine lenses: Implications for the regulation of fiber cell and overall lens volume. Exp Eye Res. 2017 Dec;165:164-174. doi: 10.1016/j.exer.2017.08.009. Epub 2017 Aug 14. PubMed PMID: 28818393.

2: AlAmri MA, Kadri H, Alderwick LJ, Simpkins NS, Mehellou Y. Rafoxanide and Closantel Inhibit SPAK and OSR1 Kinases by Binding to a Highly Conserved Allosteric Site on Their C-terminal Domains. ChemMedChem. 2017 May 9;12(9):639-645. doi: 10.1002/cmdc.201700077. Epub 2017 Apr 12. PubMed PMID: 28371477.

3: Zhang J, Deng X, Kahle KT. Leveraging unique structural characteristics of WNK kinases to achieve therapeutic inhibition. Sci Signal. 2016 Oct 18;9(450):pe3. Review. PubMed PMID: 27811182.

4: Bhuiyan MIH, Song S, Yuan H, Begum G, Kofler J, Kahle KT, Yang SS, Lin SH, Alper SL, Subramanya AR, Sun D. WNK-Cab39-NKCC1 signaling increases the susceptibility to ischemic brain damage in hypertensive rats. J Cereb Blood Flow Metab. 2017 Aug;37(8):2780-2794. doi: 10.1177/0271678X16675368. Epub 2016 Jan 1. PubMed PMID: 27798271; PubMed Central PMCID: PMC5536788.

5: Yamada K, Park HM, Rigel DF, DiPetrillo K, Whalen EJ, Anisowicz A, Beil M, Berstler J, Brocklehurst CE, Burdick DA, Caplan SL, Capparelli MP, Chen G, Chen W, Dale B, Deng L, Fu F, Hamamatsu N, Harasaki K, Herr T, Hoffmann P, Hu QY, Huang WJ, Idamakanti N, Imase H, Iwaki Y, Jain M, Jeyaseelan J, Kato M, Kaushik VK, Kohls D, Kunjathoor V, LaSala D, Lee J, Liu J, Luo Y, Ma F, Mo R, Mowbray S, Mogi M, Ossola F, Pandey P, Patel SJ, Raghavan S, Salem B, Shanado YH, Trakshel GM, Turner G, Wakai H, Wang C, Weldon S, Wielicki JB, Xie X, Xu L, Yagi YI, Yasoshima K, Yin J, Yowe D, Zhang JH, Zheng G, Monovich L. Small-molecule WNK inhibition regulates cardiovascular and renal function. Nat Chem Biol. 2016 Nov;12(11):896-898. doi: 10.1038/nchembio.2168. Epub 2016 Sep 5. PubMed PMID: 27595330.

6: Argaiz ER, Gamba G. The regulation of Na+Cl- cotransporter by with-no-lysine kinase 4. Curr Opin Nephrol Hypertens. 2016 Sep;25(5):417-23. doi: 10.1097/MNH.0000000000000247. Review. PubMed PMID: 27322883.

7: Terker AS, Zhang C, Erspamer KJ, Gamba G, Yang CL, Ellison DH. Unique chloride-sensing properties of WNK4 permit the distal nephron to modulate potassium homeostasis. Kidney Int. 2016 Jan;89(1):127-34. doi: 10.1038/ki.2015.289. Epub 2016 Jan 4. PubMed PMID: 26422504; PubMed Central PMCID: PMC4814375.

8: Zhu W, Begum G, Pointer K, Clark PA, Yang SS, Lin SH, Kahle KT, Kuo JS, Sun D. WNK1-OSR1 kinase-mediated phospho-activation of Na+-K+-2Cl- cotransporter facilitates glioma migration. Mol Cancer. 2014 Feb 20;13:31. doi: 10.1186/1476-4598-13-31. PubMed PMID: 24555568; PubMed Central PMCID: PMC3936893.

9: Picard N, Trompf K, Yang CL, Miller RL, Carrel M, Loffing-Cueni D, Fenton RA, Ellison DH, Loffing J. Protein phosphatase 1 inhibitor-1 deficiency reduces phosphorylation of renal NaCl cotransporter and causes arterial hypotension. J Am Soc Nephrol. 2014 Mar;25(3):511-22. doi: 10.1681/ASN.2012121202. Epub 2013 Nov 14. PubMed PMID: 24231659; PubMed Central PMCID: PMC3935578.

10: Sengupta S, Lorente-Rodríguez A, Earnest S, Stippec S, Guo X, Trudgian DC, Mirzaei H, Cobb MH. Regulation of OSR1 and the sodium, potassium, two chloride cotransporter by convergent signals. Proc Natl Acad Sci U S A. 2013 Nov 19;110(47):18826-31. doi: 10.1073/pnas.1318676110. Epub 2013 Nov 4. PubMed PMID: 24191005; PubMed Central PMCID: PMC3839713.

11: Park HJ, Curry JN, McCormick JA. Regulation of NKCC2 activity by inhibitory SPAK isoforms: KS-SPAK is a more potent inhibitor than SPAK2. Am J Physiol Renal Physiol. 2013 Dec 15;305(12):F1687-96. doi: 10.1152/ajprenal.00211.2013. Epub 2013 Oct 16. PubMed PMID: 24133122; PubMed Central PMCID: PMC3882447.

12: Nishida H, Sohara E, Nomura N, Chiga M, Alessi DR, Rai T, Sasaki S, Uchida S. Phosphatidylinositol 3-kinase/Akt signaling pathway activates the WNK-OSR1/SPAK-NCC phosphorylation cascade in hyperinsulinemic db/db mice. Hypertension. 2012 Oct;60(4):981-90. doi: 10.1161/HYPERTENSIONAHA.112.201509. Epub 2012 Sep 4. PubMed PMID: 22949526; PubMed Central PMCID: PMC3743028.

13: Algharabil J, Kintner DB, Wang Q, Begum G, Clark PA, Yang SS, Lin SH, Kahle KT, Kuo JS, Sun D. Inhibition of Na(+)-K(+)-2Cl(-) cotransporter isoform 1 accelerates temozolomide-mediated apoptosis in glioblastoma cancer cells. Cell Physiol Biochem. 2012;30(1):33-48. doi: 10.1159/000339047. Epub 2012 Jun 8. PubMed PMID: 22759954; PubMed Central PMCID: PMC3603147.

14: Cui Y, Huang Q, Auman JT, Knight B, Jin X, Blanchard KT, Chou J, Jayadev S, Paules RS. Genomic-derived markers for early detection of calcineurin inhibitor immunosuppressant-mediated nephrotoxicity. Toxicol Sci. 2011 Nov;124(1):23-34. doi: 10.1093/toxsci/kfr217. Epub 2011 Aug 24. PubMed PMID: 21865292; PubMed Central PMCID: PMC3196657.

15: Yagi YI, Abe K, Ikebukuro K, Sode K. Kinetic mechanism and inhibitor characterization of WNK1 kinase. Biochemistry. 2009 Nov 3;48(43):10255-66. doi: 10.1021/bi900666n. PubMed PMID: 19739668.

16: Cai H, Cebotaru V, Wang YH, Zhang XM, Cebotaru L, Guggino SE, Guggino WB. WNK4 kinase regulates surface expression of the human sodium chloride cotransporter in mammalian cells. Kidney Int. 2006 Jun;69(12):2162-70. Epub 2006 May 10. PubMed PMID: 16688122.

17: Rinehart J, Kahle KT, de Los Heros P, Vazquez N, Meade P, Wilson FH, Hebert SC, Gimenez I, Gamba G, Lifton RP. WNK3 kinase is a positive regulator of NKCC2 and NCC, renal cation-Cl- cotransporters required for normal blood pressure homeostasis. Proc Natl Acad Sci U S A. 2005 Nov 15;102(46):16777-82. Epub 2005 Nov 7. PubMed PMID: 16275913; PubMed Central PMCID: PMC1283841.